Actively Recruiting
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Led by Addpharma Inc. · Updated on 2024-05-21
280
Participants Needed
1
Research Sites
36 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of AD-209
CONDITIONS
Official Title
Phase III Study to Evaluate the Efficacy and Safety of AD-209
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Other inclusions applied
You will not qualify if you...
- Orthostatic hypotension with symptom
- Other exclusions applied
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Korea University Guro Hospital
Seoul, South Korea
Actively Recruiting
Research Team
K
Kyung Tae Kim, D.V.M
CONTACT
C
Chang Gyu Park, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here